Ratings Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
8.67 ^USD	-2.36%		-20.09%	+32.37%

May. 15	Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM
May. 09	UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company has insufficient levels of profitability.
The company's enterprise value to sales, at 3.91 times its current sales, is high.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.15B		B-
EXACT SCIENCES CORPORATION	-38.56%	8.39B		A-
GUARDANT HEALTH, INC.	+0.18%	3.32B		C
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.48B		D+
BGI GENOMICS CO., LTD.	-18.21%	2.06B	-	B-
VERACYTE, INC.	-24.57%	1.59B		C+
SEEGENE, INC.	-7.64%	704M		C+
CAREDX, INC	+8.42%	678M		C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	508M		C-
CURIOX BIOSYSTEMS CO., LTD	-6.56%	273M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes